Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease, Secondary”

137 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 137 results

Testing effectiveness (Phase 2)Study completedNCT03631407
What this trial is testing

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Who this might be right for
Colorectal Neoplasms
Merck Sharp & Dohme LLC 41
Large-scale testing (Phase 3)Active Not RecruitingNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Not applicableUnknownNCT04886193
What this trial is testing

FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

Who this might be right for
ChemotherapyGastric Cancer
Guangdong Provincial Hospital of Traditional Chinese Medicine 20
Not applicableUnknownNCT03917537
What this trial is testing

WGA in Platinum-refractory HNSCC Underwent Nivolumab

Who this might be right for
HNSCC
Chang Gung Memorial Hospital 80
Large-scale testing (Phase 3)Active Not RecruitingNCT04662710
What this trial is testing

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Who this might be right for
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLC 895
Testing effectiveness (Phase 2)Study completedNCT02255097
What this trial is testing

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 172
Testing effectiveness (Phase 2)Ended earlyNCT05709821
What this trial is testing

IMM60 and Pembrolizumab in Melanoma and NSCLC

Who this might be right for
Non-small Cell Lung CancerMelanoma
iOx Therapeutics 1
Testing effectiveness (Phase 2)Study completedNCT03284424
What this trial is testing

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

Who this might be right for
Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 159
Early research (Phase 1)Study completedNCT05594043
What this trial is testing

MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Who this might be right for
Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC 90
Large-scale testing (Phase 3)Study completedNCT03976375
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 422
Testing effectiveness (Phase 2)Study completedNCT02335411
What this trial is testing

Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 318
Large-scale testing (Phase 3)Study completedNCT05064059
What this trial is testing

Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 441
Early research (Phase 1)Active Not RecruitingNCT05382325
What this trial is testing

MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Who this might be right for
Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC 70
Early research (Phase 1)Study completedNCT03666273
What this trial is testing

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Who this might be right for
Advanced Solid TumorHead and Neck Squamous Cell Carcinoma
Bayer 60
Early research (Phase 1)Looking for participantsNCT05853367
What this trial is testing

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Who this might be right for
Metastatic Solid TumorsAdvanced Solid Tumors
Merck Sharp & Dohme LLC 178
Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160
Not applicableStudy completedNCT07192926
What this trial is testing

Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung CancerNeoplasm
Ankara Etlik City Hospital 131
Large-scale testing (Phase 3)WithdrawnNCT04859582
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Study completedNCT03322566
What this trial is testing

Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Who this might be right for
Lung Cancer
Incyte Corporation 233
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Load More Results